EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bio View's enterprise value is ₪24.84 Mil.
Bio View's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₪2.79 Mil. Therefore, Bio View's EV-to-EBITDA for today is 8.91.
The historical rank and industry rank for Bio View's EV-to-EBITDA or its related term are showing as below:
XTAE:BIOV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -63.07 Med: 8.61 Max: 107.21
Current: 8.91
During the past 13 years, the highest EV-to-EBITDA of Bio View was 107.21. The lowest was -63.07. And the median was 8.61.
XTAE:BIOV's EV-to-EBITDA is ranked better than 73.4% of 485
companies
in the Medical Devices & Instruments industry
Industry Median: 16.32
vs XTAE:BIOV: 8.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-28), Bio View's stock price is ₪0.287.
Bio View's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.005. Therefore, Bio View's PE Ratio for today is 57.40.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Bio View EV-to-EBITDA Historical Data
The historical data trend for Bio View's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bio View's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio View's EV-to-EBITDA falls into.
Bio View EV-to-EBITDA Calculation
Bio View's EV-to-EBITDA for today is calculated as:
Bio View's current Enterprise Value is ₪24.84 Mil.
Bio View's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪2.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Bio View's share price for today is ₪0.287.
Bio View's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Bio View's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTAE:BIOV has been successfully added to your 